Kiromic BioPharma is a clinical-stage immuno-oncology company dedicated to advancing natural killer (NK) cell–based therapies for patients with hard-to-treat solid tumors. The company’s approach leverages both ex vivo expanded NK cells and proprietary NK cell engager (NKE) molecules designed to harness the innate immune system against malignancies. Kiromic’s technology platforms aim to enhance tumor targeting, increase persistence of immune effector cells, and overcome common mechanisms of tumor resistance.
The company’s pipeline features a suite of investigational candidates, including KIRO-101, an off-the-shelf NKE program entering early-phase clinical evaluation, and KIRO-109, an ex vivo expanded NK cell product optimized for enhanced cytotoxicity. These programs target multiple solid tumor indications, such as triple-negative breast cancer, pancreatic ductal adenocarcinoma, and colorectal carcinoma. Kiromic also advances preclinical efforts in novel bispecific engager constructs and next-generation cell therapies intended to broaden patient access and improve response rates.
Founded in 2016 and headquartered in Houston, Texas, Kiromic BioPharma went public in 2021 via a business combination transaction and maintains research collaborations with leading cancer centers in North America and Europe. The company has scaled manufacturing capabilities to support both clinical supply and future commercial demands, while pursuing strategic partnerships to augment development resources and accelerate global access to its therapies.
Kiromic’s management team brings together seasoned leaders in oncology research, cell therapy manufacturing, and pharmaceutical development. The company’s scientific advisory board includes experts from top academic institutions, guiding clinical strategy and translational research initiatives. With a focus on innovation and patient impact, Kiromic continues to build on its foundational science to deliver next-generation immunotherapeutic solutions.
AI Generated. May Contain Errors.
